Filing Details

Accession Number:
0001104659-20-140696
Form Type:
13D Filing
Publication Date:
2020-12-31 06:13:10
Filed By:
Pw Medtech Group Ltd
Company:
China Biologic Products Inc. (NASDAQ:CBPO)
Filing Date:
2020-12-31
SEC Url:
13D Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
PW Medtech Group Limited 0 3,750,000 0 3,750,000 3,750,000 9.7%
Cross Mark Limited 0 1,374,375 0 1,374,375 1,374,375 3.5%
Liu Yufeng 0 1,374,375 0 1,374,375 1,374,375 3.5%
Filing

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13D

 

Under the Securities Exchange Act of 1934

 

(Amendment No. 11)*

 

China Biologic Products Holdings, Inc.

(Name of Issuer)

 

Ordinary Shares, Par Value $0.0001

(Title of Class of Securities)

 

G21515104

(CUSIP Number)

 

George Chen

PW Medtech Group Limited

Level 54, Hopewell Centre

183 Queen’s Road East

Hong Kong

+86 10 8478 3617

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

 

December 30, 2020

(Date of Event which Requires Filing of this Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 1(f) or 1(g), check the following box. ¨

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

 

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

SCHEDULE 13D

 

CUSIP No. G21515104    
             
1.  

Names of Reporting Persons.

PW Medtech Group Limited

2.  

Check the Appropriate Box if a Member of a Group (See Instructions).

(a) x (b) ¨

3.   SEC Use Only
4.  

Source of Funds (See Instructions)

BK

5.  

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

¨

6.  

Citizenship or Place of Organization

Cayman Islands

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

  7.  

Sole Voting Power

0

  8.  

Shared Voting Power

3,750,000 ordinary shares(1)

  9.  

Sole Dispositive Power

0

  10.  

Shared Dispositive Power

3,750,000 ordinary shares(1)

11.  

Aggregate Amount Beneficially Owned by Each Reporting Person

3,750,000 ordinary shares(1)

12.  

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

¨

13.  

Percent of Class Represented by Amount in Row (11)

9.7%(2)

14.  

Type of Reporting Person (See Instructions)

CO

               
  (1) All such Ordinary Shares will be sold to Biomedical Treasure Limited pursuant to a share purchase agreement dated October 26, 2020.
  (2) Percentage calculated based on 38,788,096 Ordinary Shares issued and outstanding as of December 18, 2020 as provided by the Issuer.
                                 

 

 2 

 

 

CUSIP No. G21515104    
             
1.  

Names of Reporting Persons.

Cross Mark Limited

2.  

Check the Appropriate Box if a Member of a Group (See Instructions).

(a) x (b) ¨

3.   SEC Use Only
4.  

Source of Funds (See Instructions)

OO

5.  

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

¨

6.  

Citizenship or Place of Organization

British Virgin Islands

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

  7.  

Sole Voting Power

0

  8.  

Shared Voting Power

1,374,375 ordinary shares

  9.  

Sole Dispositive Power

0

  10.  

Shared Dispositive Power

1,374,375 ordinary shares

11.  

Aggregate Amount Beneficially Owned by Each Reporting Person

1,374,375 ordinary shares

12.  

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

¨

13.  

Percent of Class Represented by Amount in Row (11)

3.5%(1)

14.  

Type of Reporting Person (See Instructions)

CO

               
  (1) Percentage calculated based on 38,788,096 Ordinary Shares issued and outstanding as of December 18, 2020 as provided by the Issuer.
                                 

 

 3 

 

 

CUSIP No. G21515104    
             
1.  

Names of Reporting Persons.

Liu Yufeng

2.  

Check the Appropriate Box if a Member of a Group (See Instructions).

(a) x (b) ¨

3.   SEC Use Only
4.  

Source of Funds (See Instructions)

OO

5.  

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

¨

6.  

Citizenship or Place of Organization

New Zealand

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

  7.  

Sole Voting Power

0

  8.  

Shared Voting Power

1,374,375 ordinary shares

  9.  

Sole Dispositive Power

0

  10.  

Shared Dispositive Power

1,374,375 ordinary shares

11.  

Aggregate Amount Beneficially Owned by Each Reporting Person

1,374,375 ordinary shares

12.  

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

¨

13.  

Percent of Class Represented by Amount in Row (11)

3.5%(1)

14.  

Type of Reporting Person (See Instructions)

IN

               
  (1) Percentage calculated based on 38,788,096 Ordinary Shares issued and outstanding as of December 18, 2020 as provided by the Issuer.
                                 

 

 4 

 

  

Introduction

 

This Amendment No. 11 to Schedule 13D (this “Amendment No.11”) amends and supplements the statement on Schedule 13D filed with the U.S. Securities and Exchange Commission (the “Commission”) on January 10, 2018, as amended and supplemented by the Amendment No. 1 filed under Schedule 13D/A on August 27, 2018, the Amendment No. 2 filed under Schedule 13D/A on September 24, 2018, the Amendment No. 3 filed under Schedule 13D/A on September 19, 2019, the Amendment No. 4 filed under Schedule 13D/A on January 24, 2020, the Amendment No. 5 filed under Schedule 13D/A on March 20, 2020, the Amendment No. 6 filed under Schedule 13D/A on May 5, 2020, the Amendment No. 7 filed under Schedule 13D/A on May 11, 2020, the Amendment No. 8 filed under Schedule 13D/A on September 17, 2020, the Amendment No. 9 filed under Schedule 13D/A on October 28, 2020 and the Amendment No. 10 filed under Schedule 13D/A on November 20, 2020 (the “Original Schedule 13D”), by each of PW Medtech Group Limited (“PWM”), Cross Mark Limited (“Cross Mark”), and Ms. Liu Yufeng (together with PWM and Cross Mark, the “Reporting Persons”) relating to the ordinary shares, par value $0.0001 per share (the “Ordinary Shares”) of China Biologic Products Holdings, Inc., an exempted company incorporated with limited liability under the laws of the Cayman Islands (the “Issuer”).

 

Except as provided herein, this Amendment No.11 does not modify any of the information previously reported on the Original Schedule 13D. Capitalized terms used but not defined in this Amendment No.11 have the means ascribed to them in the Original Schedule 13D.

 

Item 4. Purpose of Transaction.

 

Item 4 of the Original Schedule 13D is hereby supplemented by inserting the following after the last paragraph thereof:

 

On December 30, 2020, PWM completed the sales of (i) the 2019B Cayman Sale Shares to 2019B Cayman pursuant to the terms and conditions of the 2019B Cayman SPA and (ii) the BFL Sale Shares to BFL pursuant to the terms and conditions of the BFL SPA.

 

 5 

 

  

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: December 31, 2020

 

  PW MEDTECH GROUP LIMITED
     
  By: /s/ Yue’e Zhang
    Name: Yue’e Zhang
    Title: Executive Director and Chief Executive Officer
   
  CROSS MARK LIMITED
     
  By /s/ Liu Yufeng
    Name: Liu Yufeng
    Title: Director
   
  LIU YUFENG
     
  By  /s/ Liu Yufeng

 

 6